Systemic Levels of Anti-VEGF: What Available Data Reveal

Show Description +

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Systemic Levels of Anti-VEGF: What Available Data Reveal

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Please log in to leave a comment.

Comments

majid kheirkhahr

12 years ago

amazing.

More in Retina

From Pixels to Pathology: The Synergy of DL-Driven OCT and Wide-field Color SLO with Functional Imaging

Akio Oishi, MD, PhD; Kunihiko Akiyama, MD, PhD; Jae Rock Do, MD, PhD; Haoyu Chen, MD, PhD

Handle Diabetic Surgery Like a Pro

Dimitra Skondra, MD, PhD, FASRS and Matthew A. Cunningham, MD

Trainees at VBS 2026

Alexis Cherry, MS and Jessica D. Randolph, MD

Tips and Tricks for Teaching Surgery

Michelle Liang, MD and Jordan D. Deaner, MD